|
Thank you each for your response. It is helpful. Once we got the information from Sloan, we put a call into Caryn's NJ Onc who, we felt, could offer us a different perspective. His reaction was very interesting. Not only did he validate our concern with the logic of pulling her from the trial so quickly (while understanding it from Genentech's perspective), he's questioning wether there has been real progression (as both Lani and Chrisy pointed out). He's insisted on seeing the films and blood results before determining what our next best step is. His feeling is that reading scans is not an exact science and the perceived increase from 3.4 to 4.9 could in fact be no increase at all. Our plan is to get him the info he's asked for by next week and meet with Sloan on Tuesday to discuss their new trial suggestion. If her NJ Onc feels that there's a reasonable argument to continue the trial (Lani, I love the idea of asking for a re-scan) then I will ask him to support me in contacting Genentech (as you suggested Chrisy) to discuss this directly rather than relying on Sloan to lead our argument. If he doesn't then we will look into our next course of action including the options suggested above.
Thank you!
Eric
|